Khurram Jamil - Jan 23, 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Jan 23, 2025
Transactions value $
$0
Form type
4
Date filed
1/27/2025, 04:05 PM
Previous filing
Dec 26, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +65K $0.00 65K Jan 23, 2025 Common Stock 65K $1.23 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +60K $0.00 60K Jan 23, 2025 Common Stock 60K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026.
F3 Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement.
F4 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.